Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,952 across all filing types
Latest filing 2026-01-09 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
容诚会计师事务所（特殊普通合伙）关于回复深圳证券交易所《关于对北京利德曼生化股份有限公司的重组问询函》的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed response from an accounting firm to the Shenzhen Stock Exchange regarding a restructuring inquiry letter about Beijing Leadman Biochemical Co., Ltd. It contains extensive financial and operational details, including audit opinions, accounting treatments, sales and marketing analysis, and industry comparisons. The content is technical, focused on audit and financial verification related to a restructuring process, and includes audit institution opinions and compliance with accounting standards. It is not a full annual or quarterly report, nor a simple announcement or presentation. The document is a standalone audit-related report addressing regulatory inquiries, consistent with an Audit Report / Information filing rather than a full Annual Report or Interim Report. Therefore, the most appropriate classification is Audit Report / Information (AR). Q3 2025
2026-01-09 Chinese
关于重大资产购买报告书（草案）修订说明的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding revisions to a major asset purchase report draft by Beijing Leadman Biochemical Co., Ltd. It references a previously disclosed major asset purchase report draft and details updates made in response to an inquiry from the Shenzhen Stock Exchange. The document is short (1156 characters) and primarily serves to inform about amendments to the report rather than presenting the full report itself. It also directs readers to the full revised report disclosed on the official information disclosure platform. This fits the pattern of a Regulatory Filing (RNS) as it is an announcement about report revisions and related regulatory communications, not the full report or financial statements themselves.
2026-01-09 Chinese
北京利德曼生化股份有限公司重大资产购买报告书（草案）（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "重大资产购买报告书（草案）（修订稿）" which translates to "Major Asset Purchase Report (Draft) (Revised)". It is issued by Beijing Leadman Biochemical Co., Ltd. and involves detailed disclosures about a significant asset acquisition, including transaction parties, financial advisors, legal advisors, audit and evaluation reports, risk factors, financial data, and management discussion and analysis. The document is comprehensive and lengthy (15,000 characters), containing substantive financial and operational information related to a major asset purchase transaction. This type of document aligns with filings related to major asset purchases or restructuring disclosures, which are typically classified under Capital/Financing Update (CAP) as they pertain to significant financing or capital structure changes due to asset acquisitions. It is not an annual or interim report, nor a simple announcement or proxy statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-01-09 Chinese
中信建投证券股份有限公司关于北京利德曼生化股份有限公司本次重组相关主体买卖股票情况自查报告的核查意见
Legal Proceedings Report Classification · 95% confidence The document is a detailed self-inspection report and verification opinion regarding insider trading activities related to a major asset acquisition transaction by Beijing Lidemann Biochemical Co., Ltd. It includes extensive declarations and statements from insiders and related parties about their stock trading activities during the insider information self-inspection period. The document references regulatory rules and compliance with insider trading laws, focusing on the investigation and confirmation of insider trading or lack thereof. It is not a financial report, earnings release, or management discussion, but rather a compliance and legal-related report concerning insider trading verification tied to a major transaction. This fits the category of Legal Proceedings Report (LTR), as it deals with regulatory compliance and investigation of potential legal issues related to insider trading in connection with a major asset acquisition transaction.
2026-01-09 Chinese
北京利德曼生化股份有限公司重大资产购买报告书（草案）（修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is titled "重大资产购买报告书（草案）（修订稿）" which translates to "Major Asset Purchase Report (Draft) (Revised)". It details a significant asset acquisition by Beijing Leadman Biochemical Co., Ltd., including transaction parties, transaction price, asset evaluation, impact on the company, and related legal and financial advisor statements. The content includes detailed descriptions of the transaction, financial evaluations, and impact analysis, consistent with a major asset purchase report. This type of document is a formal report related to a significant asset acquisition, which aligns with the category of Capital/Financing Update (CAP) as it involves updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting announcement. Therefore, the correct classification is CAP with high confidence.
2026-01-09 Chinese
中信建投证券股份有限公司关于北京利德曼生化股份有限公司重大资产购买之独立财务顾问报告（修订稿）
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report (Revised)" prepared by CITIC Securities Co., Ltd. for Beijing Leadman Biochemical Co., Ltd. regarding a major asset purchase. It includes detailed sections such as transaction background, asset evaluation, compliance analysis, financial data, and legal opinions. The report is comprehensive, covering due diligence, valuation, and the impact of the transaction on the company. It is clearly a standalone advisory report related to a significant asset acquisition, fulfilling the role of an independent financial advisor's opinion on a major asset purchase transaction. This type of document is typical of an Audit Report / Information (AR) category, as it is not a full annual or interim report, nor a simple announcement or presentation. It is not a merger proxy or tender offer filing, but an independent financial advisor report related to a major asset purchase, which fits best under AR. 9M 2025
2026-01-09 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.